Oxycodone
Viewing r1 — Apr 27, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Oxycodone — oxy, percs — is a semi-synthetic opioid of the morphinan class. It is derived from thebaine and active as the parent compound,[1] with higher oral bioavailability than morphine.[2] Oxycodone is a µ-opioid receptor agonist,[3] producing its effects by suppressing pain signaling and activating reward pathways.[4]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, heroin, hydromorphone +5 moremorphine, heroin, hydromorphone, hydrocodone, fentanyl, methadone, codeine, tramadol show less
Synthesized in 1916 by Freund and Speyer at the University of Frankfurt from thebaine, oxycodone entered clinical use in Germany the following year.[5] The 1996 launch of OxyContin by Purdue Pharma, aggressively marketed for chronic non-cancer pain, became a primary catalyst of the US opioid epidemic.[6] Global consumption surpassed morphine by 2008,[5] and oxycodone remains one of the most widely prescribed opioids despite tightened guidelines, abuse-deterrent reformulations, and early-stage vaccine research.[7]
Subjective effects include profound analgesia, euphoria, sedation, and anxiolysis. The experience is a warm, heavy dissolution of physical and emotional discomfort — a blanketing calm that narrows awareness to a quiet, contented drift, often described as more euphorigenic than morphine.[2] Nausea, constipation,[8] and respiratory slowing are characteristic unsought effects.
Oxycodone produces rapid physical dependence — tolerance proceeds through a distinct molecular pathway[9] — and has a narrow therapeutic index; respiratory depression can occur within the therapeutic dose range.[10] Dose escalation narrows the safety margin as tolerance to euphoria develops faster than tolerance to respiratory depression; chronic use reshapes reward circuitry,[11] and nearly all oxycodone fatalities involve polydrug use.[12] Decades of clinical use and extensive pharmacological research provide a well-characterized safety profile.
History[edit]
Discovery
Oxycodone was synthesized in 1916 by Martin Freund and Edmund Speyer at the University of Frankfurt from thebaine — a non-analgesic opium alkaloid.[13] The synthesis sought morphine-like analgesia with reduced dependence potential, a goal only partially achieved.[13] It entered clinical use in Germany in 1917 without the approval processes required by modern standards.[5]
Clinical adoption and the opioid crisis
Oxycodone reached the United States in the 1950s in combination products — Percodan (with aspirin, 1950) and Percocet (with acetaminophen, 1976)citation needed — establishing it as a mid-tier analgesic between codeine and high-potency agents like fentanyl. The 1996 launch of OxyContin, Purdue Pharma's extended-release formulation aggressively marketed for chronic non-cancer pain, transformed prescribing patterns and became emblematic of the US opioid epidemic's first wave;[6] US opioid overdose deaths rose from approximately 4,000 in 1999 to over 47,000 in 2017.[14]
Reformulation and modern era
In 2010, OxyContin was reformulated with a crush-resistant matrix to deter non-oral abuse; surveillance confirmed reduced tampering,[15] and Canada withdrew the original formulation in 2012, replacing it with OxyNEO.[16] Current research spans pharmacogenomics,[17] oxycodone-naloxone combinations for constipation,[18] and a conjugate vaccine,[7] while CDC prescribing guidelines were updated in 2016[19] and 2022.[20]
The name "oxycodone" derives from its chemical relationship to codeine: "oxy-" from the 14-hydroxy group and "-codone" marking the C-6 ketone. Street names — oxy, OC, percs (for Percocet combinations) — reflect how thoroughly branded formulations shaped popular awareness of the drug.
Chemistry[edit]
Structural class
Oxycodone belongs to the morphinan chemical family — the same pentacyclic scaffold shared by morphine, codeine, hydrocodone, and hydromorphone. It is a semi-synthetic derivative of thebaine (paramorphine), a minor opium alkaloid that lacks analgesic activity but serves as a versatile precursor for 14-hydroxymorphinan opioids.[2]
The morphinan core consists of a phenanthrene system fused with a piperidine ring and an oxygen-bridged furan ring. Oxycodone differs from morphine at two positions: a methoxy group at position 3 (replacing morphine's free hydroxyl) and a carbonyl at C-6 (replacing morphine's hydroxyl). These substitutions reduce first-pass metabolism, accounting for oxycodone's substantially higher oral bioavailability compared to morphine.
Molecular properties
| Molecular formula | C18H21NO4 |
| Molecular weight | 315.36 g/mol |
Properties confirmed via published characterization.[5][21]
Stereochemistry
Oxycodone possesses four defined stereocenters (4R, 4aS, 7aR, 12bS) and exists as a single enantiomer — not a racemic mixture.[5] The absolute configuration is locked within the rigid pentacyclic scaffold, and all pharmaceutical preparations consist of this single stereoisomeric form.
Physical properties
Oxycodone base is a white crystalline solid with a melting point of 218–220°C and limited aqueous solubility; pharmaceutical formulations typically use the hydrochloride salt for improved dissolution.[21] At physiological pH (7.4), its pKa of 8.53 predicts that approximately 93% exists in protonated form, influencing membrane permeability and blood-brain barrier penetration.
Pharmacology[edit]
Mechanism of action
Oxycodone acts primarily as an agonist at the µ-opioid receptor (μ-opioid), a G-protein coupled receptor distributed throughout the central and peripheral nervous systems.[4] Receptor activation triggers a signaling cascade that reduces neuronal excitability: intracellular cAMP decreases, potassium channels open to hyperpolarize the cell membrane, and calcium channels close — collectively suppressing pain transmission.[4]
Multi-receptor screening confirmed MOR as oxycodone's dominant target, with no significant activity at δ-opioid, cannabinoid, sigma, or monoamine transporter sites.[3] A secondary action at kappa-opioid receptors has been demonstrated in animal neuropathic pain models,[22] though its clinical relevance remains uncertain.
Analgesia is driven by the parent compound rather than its metabolites. Blocking the enzyme that converts oxycodone to the potent metabolite oxymorphone does not meaningfully alter pain suppression,[1] confirming direct MOR activation by oxycodone itself as the therapeutic mechanism.
Tolerance
Oxycodone tolerance proceeds through a molecular pathway distinct from morphine: GRK3-mediated receptor desensitization rather than the JNK pathway morphine uses.[9] This divergence provides a cellular basis for incomplete cross-tolerance between the two drugs despite their shared receptor target.[9]
Pharmacokinetics
Oral bioavailability is 60–87%[2] — substantially higher than morphine's 20–30%, owing to reduced first-pass liver metabolism. Peak plasma levels are reached in approximately 1–1.5 hours for immediate-release and 2–3 hours for controlled-release formulations.[2][5] Plasma protein binding is approximately 45%.[23]
The liver metabolizes oxycodone through two main enzyme pathways: CYP3A4 (the primary route, producing the weakly active noroxycodone) and CYP2D6 (a secondary route, producing the potent but clinically minor oxymorphone).[24] Plasma half-life is 3–5 hours for immediate-release formulations.[2][23] Controlled-release versions extend effective duration to approximately 12 hours through slowed absorption.[2] Elimination is primarily through the kidneys.
Neuroscience[edit]
Where it acts
Oxycodone's rewarding effects originate in the ventral tegmental area (VTA), where μ-opioid activation disinhibits dopamine neurons projecting to the nucleus accumbens — the brain's core reward hub. This dopamine surge drives the euphoria and positive reinforcement that make the drug compelling. Dopamine D3 receptors play a specific role: blocking them reduces oxycodone self-administration and drug-seeking in animal models.[25]
Pain suppression operates through a separate circuit. MOR activation in the periaqueductal gray engages descending inhibitory pathways that suppress pain signals at the spinal cord level, reducing the release of pain-signaling molecules from sensory neurons.[4]
Why it matters
Chronic oxycodone exposure shifts the brain's motivational balance. DeltaFosB — a long-lasting transcription factor — accumulates in the nucleus accumbens during repeated use, driving synaptic changes that sustain compulsive drug-seeking well beyond the period of active use.[11]
This shift maps onto opponent process dynamics: early use produces strong euphoria followed by mild rebound effect discomfort, but with repeated dosing, tolerance erodes the euphoria while the rebound intensifies. The motivational engine transitions from seeking pleasure to escaping distress — a hallmark of established dependence. Glial cells may amplify this process; minocycline, which suppresses glial activation, reduced positive subjective responses to oxycodone in non-dependent users.[26]
Subjective Effects[edit]
Oxycodone's subjective character is shaped by route of administration more than most opioids. Oral dosing produces a gradual, sustained warmth and contentment — a slow tide of calm settling over the body. Insufflated or intravenous use compresses the onset into a distinct euphoric rush that drives compulsive redosing. Set and setting strongly modulate whether the experience registers as therapeutic relief or recreational intoxication: the same dose that produces quiet analgesia in a pain patient may produce nodding euphoria in a recreational context.
Compared with morphine, oxycodone is frequently described as more euphorigenic and more sedating, with less nausea and pruritus.[2] Relative to hydromorphone, it occupies a lower-potency position with longer duration and higher oral bioavailability, making it the more common oral opioid of misuse.
Effect Grid
At common oral doses (10–30 mg), the full opioid experience manifests: pronounced euphoria, deep physical relaxation, significant analgesia, and a pervasive sense of contentment and emotional insulation. Cognitive effects include thought deceleration, reduced motivation, and dreamy mentation. Social inhibition decreases; conversations feel effortless. Music appreciation is enhanced.
Physically, constipation becomes likely, miosis is pronounced, and pruritus may intensify. Nausea occurs in a significant minority. Sedation increases substantially — the "nod" (oscillation between drowsiness and wakefulness) may begin at the upper end of this range. Respiratory rate begins to decrease.
Functional capacity is significantly impaired. The experience typically commits the user for 4–6 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sedation · Body high · Bodily heaviness · Tactile euphoria · Sexual arousal suppression · Spontaneous body sensations · Nausea · Muscle relaxation · Physical fatigue · Appetite suppression · Excessive sweating · Dizziness · Dry mouth · Temperature dysregulation · Vomiting · Bodily dissociation
Tactile euphoria · Sexual arousal suppression · Spontaneous body sensations · Nausea · Muscle relaxation · Physical fatigue · Appetite suppression · Excessive sweating · Dizziness · Dry mouth · Vomiting · Bodily dissociation
Motivation suppression · Confusion · Thought disorganization
Anxiety · Dysphoria
Sociability enhancement · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Cognitive disconnection
Timeline
First perceptible effects emerge as a subtle warmth in the chest and mild mood shift. Onset timing is dose-dependent and influenced by stomach contents.
Warmth spreads through the body. Analgesia, anxiolysis, and emerging euphoria build steadily. Mild pruritus and nausea may appear.
Maximum euphoria, analgesia, and sedation. The characteristic opioid warmth and emotional insulation are at their strongest. Nodding may occur at higher doses.
Effects remain clearly present but intensity has plateaued below peak levels. Sedation and contentment persist. Constipation and miosis continue.
Gradual return toward baseline. Analgesia and mood effects diminish progressively. Residual drowsiness and mild cognitive slowing persist.
Subtle residual warmth, mild contentment, or slight drowsiness may persist. Constipation may continue well beyond subjective resolution.
⚠ Do not drive or operate heavy machinery for at least 6 hours after subjective effects resolve, as psychomotor impairment outlasts perceived sobriety.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · hydromorphone
Toxicity
Acute toxicity
Oxycodone has a narrow therapeutic index — the gap between an effective dose and a dangerous one is small, and respiratory depression can occur within the therapeutic range in opioid-naive or medically vulnerable individuals.[10] Overdose presents as slowed or stopped breathing, pinpoint pupils, decreased consciousness, slow heart rate, low blood pressure, low body temperature, muscle limpness, and cold skin. Death occurs from respiratory failure.[23]
Analysis of 1,014 oxycodone-involved postmortem cases found that 96.7% involved multiple substances.[12] Only 30 deaths (3.3%) involved oxycodone alone, indicating that polydrug use — particularly with benzodiazepines, alcohol, and other depressants — is the dominant fatality pattern.[12]
Chronic toxicity
Long-term use is associated with immune suppression, particularly in elderly populations.[10] Chronic opioid exposure disrupts hormonal function, reducing testosterone in men and estrogen in women, contributing to sexual dysfunction, fatigue, and bone density loss.citation needed
Neonatal effects
Use during pregnancy can cause neonatal opioid withdrawal, with symptoms typically appearing within the first day of life.[27] Animal studies show long-term sex-dependent effects on brain development, including altered sensory processing.[28]
Pharmacogenomic risk
Individuals who are ultrarapid metabolizers of CYP2D6 produce more of the potent metabolite oxymorphone and may experience enhanced side effects at standard doses.[17]
Psychological risks
Oxycodone's high reinforcing properties and the neuroplastic changes from chronic use create substantial psychological risk. DeltaFosB accumulation in reward circuits drives persistent changes in motivation that outlast active use.[11]
Opioid misuse rates of 21–29% and addiction rates of 8–12% have been documented in chronic pain patients receiving opioids including oxycodone.[29] Prescription opioid use is associated with subsequent transition to heroin in a subset of users.[30] Dysphoria, anxiety, and insomnia during withdrawal contribute to relapse, and psychological craving persists long after physical withdrawal resolves.
Tolerance & Dependence
Tolerance develops with repeated use, requiring escalating doses for the same analgesic or euphoric effect.[2] Tolerance to sedation and nausea develops faster than tolerance to constipation, which persists throughout use.[8]
Physical dependence develops with prolonged use. Abrupt cessation produces withdrawal characterized by anxiety, muscle aches, diarrhea, insomnia, sweating, and intense craving.[31][32]
Cross-tolerance exists with all µ-opioid agonists — morphine, hydromorphone, fentanyl, Heroin — though it is incomplete due to divergent cellular tolerance mechanisms.[9]
Drug interactions
The most dangerous interactions involve co-administration with other central nervous system depressants, producing additive or synergistic respiratory depression.
Alcohol produces additive respiratory and CNS depression and is among the most common co-intoxicants in oxycodone deaths.[12]
Benzodiazepines represent the most frequently lethal combination. Controlled studies show augmented abuse-related effects and impaired coordination with oxycodone and alprazolam,[33] and benzodiazepines were the most common co-intoxicant in oxycodone postmortem cases.[12]
Gabapentinoids (pregabalin, gabapentin) co-prescribed with opioids significantly increase the risk of opioid-related death.[34][35]
Serotonergic drugs (SSRIs, SNRIs, MAOIs) can produce serotonin syndrome when combined with oxycodone, despite oxycodone not directly blocking serotonin reuptake.[36][37] The risk is lower than with tramadol but not zero.
CYP3A4 inhibitors substantially increase oxycodone blood levels and represent the most significant pharmacokinetic interaction.[38] CYP3A4 inducers decrease levels and may cause treatment failure.[38][39]
Contraindications
Absolute contraindications
- Pre-existing respiratory depression — oxycodone further suppresses breathing drive
- Acute breathing difficulty or elevated carbon dioxide levels
- Known allergy to oxycodone or any formulation component
- Bowel obstruction — oxycodone slows gut motility, worsening the blockage[23]
Relative contraindications
- Concurrent MAOI use — risk of serotonin syndrome and enhanced CNS depression
- Concurrent CYP3A4 inhibitor use — substantially increases oxycodone exposure[38]
- Liver impairment — slowed metabolism prolongs drug effects
- Kidney impairment — reduced excretion of oxycodone and metabolites
- Pregnancy — risk of neonatal withdrawal syndrome[27]
- Elderly patients — reduced clearance and increased sensitivity[10]
- History of substance use disorder — high reinforcing properties increase relapse risk
Harm Reduction[edit]
Forms & Identification
Oxycodone circulates as pharmaceutical tablets (immediate-release and extended-release), capsules, and oral solutions. In unregulated markets, diverted pharmaceutical pills are common, but counterfeit tablets pressed with fentanyl or fentanyl analogs represent a growing and potentially lethal risk. No visual inspection can reliably distinguish a genuine pharmaceutical tablet from a counterfeit.
Fentanyl test strips are the single most important harm reduction tool for anyone using oxycodone obtained outside a pharmacy. Even a single counterfeit pill can deliver a fatal dose of fentanyl. Testing every batch — and ideally every pill — is a minimum standard.
Guidelines
- Test all non-pharmacy oxycodone with fentanyl test strips before use
- Start with the lowest effective dose, particularly after any period of abstinence — tolerance drops rapidly and a previously tolerated dose can be fatal
- Keep naloxone accessible and ensure companions know how to administer it
- Avoid crushing or tampering with extended-release formulations — this releases the full dose at once and can cause overdose
- Do not use alone — have someone present who can recognize and respond to overdose
- Space doses to allow full clearance; do not redose before the previous dose has peaked
- Eat beforehand — opioids on an empty stomach increase nausea and may accelerate absorption
Set & Setting
Oxycodone's sedating and respiratory-depressant effects make environment critical to safety. Use in the presence of a sober companion who can monitor breathing and respond to overdose is strongly advisable. Avoid situations where falling asleep unmonitored is likely — respiratory depression during sleep is a primary mechanism of opioid death.
Comfortable, familiar surroundings reduce the likelihood of anxiety-driven redosing. Having naloxone physically present — not stored in another room or vehicle — is a baseline precaution.
Aftercare & integration. After opioid use, physical recovery centers on hydration, nutrition, and sleep — opioids suppress appetite and disrupt normal sleep architecture. Constipation may persist for days; adequate fiber and fluid intake help restore normal bowel function.
For individuals using oxycodone for pain management, honest assessment of whether the drug is still serving its therapeutic purpose — or has become a source of dependence — is a recurring question worth revisiting with a trusted clinician. Escalating doses, use beyond prescribed amounts, or using to manage emotional rather than physical pain are signs that the relationship with the drug has shifted.
Recovery & Support
Oxycodone dependence is treatable. Medication-assisted treatment with buprenorphine or methadone remains the most evidence-supported approach, reducing both withdrawal severity and relapse risk. Clonidine can manage acute withdrawal symptoms including anxiety, agitation, and sweating.[31]
Abrupt cessation after prolonged use produces withdrawal — not life-threatening but intensely uncomfortable, typically peaking 24–72 hours after the last dose and resolving over 7–10 days. Medical supervision during detoxification is strongly recommended. Long-term support through peer groups, counseling, or structured treatment programs addresses the psychological component of dependence that persists well beyond physical withdrawal.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow, shallow, or stopped breathing. Blue or gray lips, fingertips, or skin. Unresponsive to voice or sternal rub. Gurgling or snoring sounds while unconscious. Any of these signals require immediate action.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available (intranasal or intramuscular) — it reverses opioid overdose within minutes
- 3. Place the person in the recovery position (on their side) to prevent choking
- 4. If breathing has stopped and you are trained, begin rescue breathing
- 5. Stay with the person — naloxone wears off in 30–120 minutes, and oxycodone's effects last longer; a second dose may be needed
- 6. Do NOT induce vomiting; do NOT leave the person alone
What to tell the dispatcher: The substance (oxycodone or suspected opioid), the amount if known, when it was taken, current symptoms, and whether naloxone has been given. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Reversal agent: Naloxone is a complete opioid antagonist available over-the-counter in many jurisdictions as nasal spray (Narcan) or injectable.[23] It reverses oxycodone-induced respiratory depression, but its duration is shorter than oxycodone's, making repeat dosing and medical monitoring essential. As of 2014, community naloxone programs in the US had documented approximately 26,463 overdose reversals.[40]
Legal Status[edit]
Oxycodone is controlled internationally under the 1961 United Nations Single Convention on Narcotic Drugs and classified as a prescription-only narcotic in all major jurisdictions. Its scheduling reflects both accepted medical utility and high abuse potential, placing it among the most restrictively controlled substances that retain clinical availability.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | High abuse potential with accepted medical use. No refills permitted; requires written or electronic prescription. Schedule II since 1970.[41] |
| United Kingdom | Class A drug; Schedule 2 Controlled Drug (CD2) | Misuse of Drugs Act 1971. Possession without prescription: up to 7 years imprisonment. Supply or production: up to life imprisonment.[42] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Original OxyContin withdrawn February 2012; replaced by abuse-deterrent OxyNEO. Prescription required.[42] |
| Australia | Schedule 8 (Controlled Drug) | Strict state-level prescribing regulations. Possession without authority is illegal.[42] |
| European Union | Varies by member state | Generally classified as a prescription-only narcotic under national equivalents of the UN Single Convention. Individual member states set prescribing and dispensing controls. |
references
- [1] ^abLemberg KK, Heiskanen TE, Neuvonen M, et al. (2010) Does co-administration of paroxetine change oxycodone analgesia — Scandinavian Journal of Pain doi:10.1016/j.sjpain.2009.09.003
- [2]
- [3] ^abOlson KM, Duron DI, Womer D, Fell R, Streicher JM (2019) Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids — PLoS ONE doi:10.1371/journal.pone.0217371
- [4] ^abcdHerman TF, Cascella M, Muzio MR, et al. (2026) Mu Receptors (StatPearls/NCBI) — Pharmacology, Biochemistry and Behavior (via StatPearls) PMID:31855381
- [5]
- [6] ^abKolodny A, Courtwright DT, Hwang CS, et al. (2015) The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction — Annual Review of Public Health doi:10.1146/annurev-publhealth-031914-122957